Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22939563 | 0.83 | MEN1 (0.39) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| Bromide SCHEMBL5382542 | 0.82 | IDO1 (0.35) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22939561 | 0.79 | MEN1 (0.41) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4173041 | 0.79 | SMN1; SMN2 (0.36) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4169708 | 0.76 | KMT2A (0.33) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3753144 | 0.76 | KMT2A (0.33) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4164008 | 0.76 | KMT2A (0.33) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13930385 | 0.75 | PKM (0.38) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4171206 | 0.73 | MEN1 (0.35) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4171295 | 0.73 | MEN1 (0.35) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298141-A1 | SUBSTITUTED PYRIDINE N-OXIDE HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298141-A1 | SUBSTITUTED PYRIDINE N-OXIDE HERBICIDES | CYP3A7, CYP2W1, CBR3 | MEN1 3920/4885KMT2A 3291/4885CYP1A2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.